<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01506336</url>
  </required_header>
  <id_info>
    <org_study_id>AB07001</org_study_id>
    <nct_id>NCT01506336</nct_id>
  </id_info>
  <brief_title>Masitinib in Patients With Gastro-Intestinal Stromal Tumour Resistant to Imatinib</brief_title>
  <official_title>A Prospective, Multicenter, Randomized, Open-label, Active Controlled, 2-parallel Group, Phase II Study to Compare Efficacy and Safety of Masitinib at 12 mg/kg/Day to Sunitinib at 50 mg/Day in Treatment of Patients With Gastro-intestinal Stromal Tumor Resistant to Imatinib</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AB Science</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AB Science</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective is to compare efficacy and safety of masitinib at 12 mg/kg/day to sunitinib at
      50 mg/day in treatment of patients with gastro-intestinal stromal tumor resistant to
      imatinib.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall progression free survival</measure>
    <time_frame>up to 36 weeks</time_frame>
    <description>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>up to 36 weeks</time_frame>
    <description>From date of randomization until the date of death from any cause, assessed up to 36 weeks</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Gastro Intestinal Stromal Tumor</condition>
  <arm_group>
    <arm_group_label>masitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>masitinib 12 mg/kg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sunitinib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>sunitinib 50 mg/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>masitinib</intervention_name>
    <description>masitinib 12 mg/kg/day</description>
    <arm_group_label>masitinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sunitinib</intervention_name>
    <description>sunitinib 50 mg/day</description>
    <arm_group_label>sunitinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histological proven, metastatic, or locally advanced and non-operable GIST

          2. Measurable tumor lesions with longest diameter ≥ 20 mm using conventional techniques
             or ≥ 10 mm with spiral CT scan according RECIST criteria

          3. C-kit (CD117) positive tumors detected immuno-histochemically and documented mutation
             of c-kit at any time if available

          4. Patients resistant to imatinib at dose of 400 mg/day

        Exclusion Criteria:

          1. Patient treated for a cancer other than GIST cancer within 5 years before enrolment,
             with the exception of basal cell carcinoma or cervical cancer in situ

          2. Patient with active central nervous system (CNS) metastasis or with history of CNS
             metastasis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Axel Le Cesne, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Gustave Roussy, Villejuif, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute Gustave Roussy (IGR)</name>
      <address>
        <city>Villejuif</city>
        <zip>94815</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4143095/</url>
    <description>Publication of clinical study results</description>
  </link>
  <results_reference>
    <citation>Adenis A, Blay JY, Bui-Nguyen B, Bouché O, Bertucci F, Isambert N, Bompas E, Chaigneau L, Domont J, Ray-Coquard I, Blésius A, Van Tine BA, Bulusu VR, Dubreuil P, Mansfield CD, Acin Y, Moussy A, Hermine O, Le Cesne A. Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: a randomized controlled open-label trial. Ann Oncol. 2014 Sep;25(9):1762-9. doi: 10.1093/annonc/mdu237. Epub 2014 Jul 25.</citation>
    <PMID>25122671</PMID>
  </results_reference>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>January 3, 2012</study_first_submitted>
  <study_first_submitted_qc>January 5, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2012</study_first_posted>
  <last_update_submitted>December 8, 2018</last_update_submitted>
  <last_update_submitted_qc>December 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GIST</keyword>
  <keyword>resistant</keyword>
  <keyword>imatinib</keyword>
  <keyword>gastro intestinal stromal tumor resistant to imatinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sunitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

